Crossmark

Early advanced therapies and real-world outcomes in Crohn's disease: A population-based comparison of two incident cohorts in Navarra

Crossref DOI link: https://doi.org/10.1016/j.gastrohep.2025.502540

Published Print: 2026-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Elosua, Alfonso

Nantes, Óscar

Chaparro, María

Zabalza, Lucía

Irisarri, Rebeca

Vicuña, Miren

Kutz, Marcos

Rubio, Saioa

Librero, Julián

Angós, Ramón

Garre, Ana

Gisbert, Javier P.

Rodríguez, Cristina
Funding

Funding for this research was provided by:

Carlos III Health Institute (PI16/01296)

Carlos III Health Institute (FI17/00143)

MSD

Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
License Information

Text and Data Mining valid from 2026-02-01

Text and Data Mining valid from 2026-02-01

stm-asf valid from 2026-02-01

stm-asf valid from 2026-02-01

stm-asf valid from 2026-02-01

stm-asf valid from 2026-02-01

stm-asf valid from 2026-02-01
More Information

This article is maintained by: Elsevier

Article Title: Early advanced therapies and real-world outcomes in Crohn's disease: A population-based comparison of two incident cohorts in Navarra

Journal Title: Gastroenterología y Hepatología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastrohep.2025.502540

Content Type: article

Copyright: © 2025 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.